Anti-Rheumatic Drugs - Drugs used for arthritic disorders Flashcards

1
Q

Treatment of osteoarthritis (3)

A
  1. Pain Relief & Anti-inflammatory
    - Acetaminophen, non-selective NSAIDs, COX-2 inhibitors, glucocorticoids
  2. Viscosupplementation
    - Intra-articular hyaluronic acid - shock absorption, protective coating of cartilage, lubrication, reduce pain, induce biosynthesis of hyaluronic acid & ECM
  3. Symptomatic slow-acting drugs for OA
    - Chondroitin sulphate, glucosamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Classes of drugs used in gouty arthritis & examples

A

Anti-Inflammatory: relieve acute gouty attack

  1. NSAIDs & COX-2 inhibitors (indomethacin, naproxen, celecoxib)
  2. Glucocorticoids (prednisolone - oral/intra-articular injection)
  3. Colchicine

Urate-Lowering Therapy: prevent recurrent gouty episodes

  1. Xanthine oxidase inhibitors (Allopurinol, Febuxostat)
  2. Uricosuric agents (Probenecid, sulfinpyrazone)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

NSAIDs & COX-2 inhibitors in gouty arthritis

A
  • Inhibit production of prostaglandins & urate crystal phagocytosis
  • Contraindications: low dose of aspirin/salicylates - anti-uricosuric actions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mechanism of action of colchicine

A
  1. Binds to tubulin - prevents tubulin polymerization into microtubules
  2. Inhibits leukocyte migration & phagocytosis, inhibits leukotriene B4 production
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Uses of colchicine

A
  1. Relieve pain & inflammation in acute gouty attack in 12-24h (fast action)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Toxicity of colchicine (3)

A
  1. Diarrhea, nausea, vomiting, abdominal pain
  2. Muscle weakness
  3. Allergic reactions `
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mechanism of allopurinol

A

Decreases uric acid production by inhibiting xanthine oxidase enzyme (oxidation of xanthine to uric acid)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Uses of allopurinol (3)

A
  1. Debilitating gout attacks (target uric acid<6.0mg/dL)
  2. Chronic erosive arthritis
  3. Urate nephrolithiasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Toxicity of allopurinol (5)

A
  1. Allopurinol Hypersensitivity Syndrome eg Stevens-Johnson syndrome - risk factors - renal impairment with creatinine clearance <60ml/min, thiazide therapy, HLA-B58 antigen
  2. Skin rash
  3. Vasculitis
  4. Diarrhea
  5. Hepatitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mechanism of action of uricosuric agents

A

Inhibits anion transport sites at proximal tubule - inhibits uric acid reabsorption + increases uric acid excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Uses of uricosuric agents (3)

A
  1. When allopurinol is contraindicated
  2. Tophaceous gout
  3. Increasingly frequent gouty attack
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Toxicity of uricosuric agents (4)

A
  1. Allergic reactions, rash, swelling
  2. Nephrotic syndrome
  3. Severe lower back pain
  4. Maintain large urine volume to prevent urolithiasis, increase urine pH by alkali eg potassium citrate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Classes of drugs used in rheumatoid arthritis & examples

A

Anti-Inflammatory

  1. NSAIDs - short term relief of pain & stiffness + PPI to reduce GI side effects
  2. Glucocorticoids

Synthetic/Non-biologic DMARDs

  1. Methotrexate +
  2. Hydroxychloroquine (best tolerated) or sulfasalazine, leflunomide, immunosuppressants

Biological DMARDs

  1. Anti-TNF-α (Infliximab, adalimumab, etanercept)
  2. Anti-IL-1 receptor (anakinra)
  3. Anti-CD20 (rituximab)
  4. Anti-CTLA41g (abatacept)
  5. Anti-IL-6 receptor (tocilizumab)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Mechanism of action of methotrexate

A
  1. Folic acid analog, inhibits AICAR transformylase
  2. Inhibits thymidylate synthetase
  3. Inhibits dihydrofolate reductase (minor)
  4. Increases extracellular adenosine levels & activates adenosine A2a receptor
    - anti-proliferative effects on T cells & inhibition of macrophage function
    - decrease in pro-inflamm cytokines, adhesion molecules, chemotaxis, phagocytosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Toxicity of methotrexate (5)

A
  1. Myelosuppression
  2. Mouth & GI ulcers
  3. Hepatic fibrosis
  4. Pneumonitis
  5. Teratogenic effects
  • Concomitant folic/folinic acid given 12-24h after methotrexate decreases toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Mechanism of action & uses of hydroxychloroquine

A
  • Mechanism unclear, involves suppression of T cell response, decreased chemotaxis & inhibition of DNA & RNA synthesis
  1. Used with methotrexate in RA
  2. Anti-malarial agent
17
Q

Toxicity of hydroxychloroquine (3)

A
  1. Ocular toxicity
  2. Dyspepsia
  3. Nausea, vomiting
18
Q

Mechanism of action of sulfasalazine

A
  1. Decreased IgA & IgM rheumatoid factors
  2. Suppression of T & B cells, and macrophages
  3. Decrease in inflammatory cytokines eg IL-1β, TNF-α, IL-6
19
Q

Toxicity of sulfasalazine (5)

A
  1. Nausea, vomiting
  2. Headache
  3. Rash
  4. Hemolytic anemia, neutropenia
  5. Reversible infertility in men
20
Q

Mechanism of action of leflunomide

A
  1. Inhibits dihydroorotate dehydrogenase
  2. Decrease in pyrimidine synthesis & growth arrest at GI phase
  3. Inhibits T cell proliferation & B cell autoantibody production
  4. Inhibits NF-kB activation pro-inflammatory pathway
21
Q

Toxicity of leflunomide (5)

A
  1. Diarrhea
  2. Elevation of liver enzymes
  3. Alopecia
  4. Weight gain
  5. Teratogenic
22
Q

Uses of anti-TNF-α

A
  1. RA patients who do not respond well with DMARD therapy

2. Used with methotrexate for optimal effects (and prevents human anti-chimeric Ab prod)

23
Q

Toxicity of anti-TNF-α & Contraindications (7+2)

A
  1. Respiratory infection
  2. Skin infection
  3. Increased risk of lymphoma
  4. Optic neuritis
  5. Exacerbation of multiple sclerosis
  6. Leukopenia
  7. Aplastic anemia
  8. Live vaccination
  9. Hepatitis B
24
Q

Mechanism of action of anakinra

A
  1. Recombinant IL-1R antagonist, binds to IL-1 receptor - bloocks signalling
    - less effective than anti-TNF
25
Q

Toxicity of anakinra (2)

A
  1. Infections

2. Injection site reactions

26
Q

Mechanism of action of rituximab

A
  1. Chimeric mAb IgG directed at CD20 on B cells - depletes CD20+ B cells
  2. Blocks Ag presentation, autoantibody & cytokine level
27
Q

Toxicity of rituximab (2)

A
  1. Rash in first dose

2. Respiratory infection in COPD

28
Q

Mechanism of action & uses of abatacept

A

Recombinant fusion protein with CTLA4-FcIgG1 (IV), binds to CD80 & CD86 & prevents CD28 activation

  1. T cell therapy, IV
29
Q

Toxicity of abatacept (2)

A
  1. Respiratory infection in COPD

2. Increased lymphoma incidence

30
Q

Mechanism of action of tocilizumab

A

Humanized mAb IgG1 directed at IL-6Rα chain - prevents binding of IL-6 to IL-6Rα and homodimerization of IL-6Rβ signalling

31
Q

Toxicity of tocilizumab (7)

A
  1. Infections
  2. Skin eruptions
  3. Stomatitis
  4. Fever
  5. Neutropenia
  6. Increase in ALT/AST
  7. Hyperlipidemia